A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Texas hairstylist Tim Bo Mack opened up to PEOPLE about his years-long struggle to lose weight. He finally found success ...

The GLP-1 conversation is fundamentally a conversation about women’s health access — and we need to start treating it that ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

People taking GLP-1 agonists for diabetes have a significantly lower risk of developing dementia compared to those using ...

Use of GLP-1 receptor agonists is associated with a lower risk of death than use of DPP4 inhibitors in older patients with cancer and type 2 diabetes, data suggest.

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the ...